For example, a dual‐specificity TKI, lapatinib, showed synergistic inhibitory effects when combined with trastuzumab and applied on HER2‐overexspressing breast cancer cell lines (Xia et al,2002). This evidence concerns the gene ERBB2 and breast carcinoma.